Healthcare - Biotechnology - NASDAQ - US
$ 9.68
-4.06 %
$ 2.89 B
Market Cap
-28.47
P/E
CASH FLOW STATEMENT
-69.1 M
OPERATING CASH FLOW
98.1 M
INVESTING CASH FLOW
61.7 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Amicus Therapeutics, Inc.
| Net Income | -152 M |
| Depreciation & Amortization | 7.87 M |
| Capital Expenditures | -7.44 M |
| Stock-Based Compensation | 86.1 M |
| Change in Working Capital | -48 M |
| Others | 9.01 M |
| Free Cash Flow | -76.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | Dec-2006 | Dec-2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||||||||||||||
| Net Income | (151.6) | (236.6) | (250.5) | (276.9) | (356.4) | (349.0) | (284.0) | (200.0) | (132.1) | (68.9) | (59.6) | (48.8) | (44.4) | (54.9) | (6.6) | (39.4) | (41.2) | (46.3) | (20.0) |
| Depreciation & Amortization | 7.9 | 5.3 | 6.2 | 8.8 | 4.8 | 4.2 | 3.6 | 3.2 | 1.8 | 1.5 | 1.7 | 1.7 | 1.6 | 2.1 | 2.1 | 1.5 | 1.2 | 1.0 | 0.7 |
| Deferred Income Tax | (4.9) | 9 K | 34 K | (0.2) | (1.4) | 6.0 | (167.3) | (3.7) | 1.0 | 0 | (0.9) | 0 | 0 | 0.1 | 0 | (6.4) | (2.8) | 0 | 0 |
| Stock Based Compensation | 86.1 | 76.5 | 57.8 | 49.2 | 44.4 | 29.3 | 23.1 | 17.5 | 10.0 | 6.0 | 6.2 | 6.2 | 8.7 | 6.2 | 7.8 | 6.4 | 2.8 | 0 | 0 |
| Other Operating Activities | 41.5 | 28.0 | 2.5 | 17.8 | 46.6 | 14.3 | 234.9 | 31.4 | 4.9 | 0.3 | 2.0 | (0.6) | (2.8) | 1.4 | 0.2 | 6.4 | 4.1 | 4.5 | 0.4 |
| Change in Working Capital | (48.0) | (39.9) | (18.6) | (32.1) | 11.6 | (4.7) | (25.8) | 1.1 | 14.3 | 9.4 | 4.9 | 7.8 | (12.5) | 31.2 | (46.9) | (5.5) | 51.0 | 7.0 | 0.8 |
| Cash From Operations | (69.1) | (166.6) | (202.5) | (233.3) | (250.4) | (300.0) | (215.5) | (150.5) | (100.1) | (51.7) | (45.8) | (33.7) | (49.4) | (14.0) | (43.4) | (36.9) | 15.2 | (33.9) | (18.1) |
| INVESTING CASH FLOW | |||||||||||||||||||
| Capital Expenditures | (7.4) | (3.8) | (3.9) | (3.2) | (20.0) | (6.3) | (4.5) | (6.0) | (4.8) | (0.2) | (0.7) | (4.3) | (1.4) | (0.4) | (1.8) | (2.7) | (0.7) | (2.0) | (3.0) |
| Other Items | 105.5 | 96.1 | 82.6 | (10.4) | 115.2 | (114.9) | (166.7) | 1.4 | (140.5) | (106.8) | 26.8 | (35.1) | 47.9 | (19.1) | 33.7 | 24.4 | (74.4) | (24.6) | (13.9) |
| Cash From Investing Activities | 98.1 | 92.3 | 78.8 | (13.6) | 95.2 | (121.2) | (171.2) | (4.5) | (145.3) | (107.1) | 26.1 | (39.4) | 46.5 | (19.4) | 31.9 | 21.7 | (75.0) | (26.6) | (16.9) |
| FINANCING CASH FLOW | |||||||||||||||||||
| Common Stock Repurchased | 0 | (11.5) | 0 | (10.0) | (3.2) | (2.8) | (1.6) | (1.3) | (2.0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (21.0) | (0.3) | (0.5) | 230.6 | 19.5 | 146.3 | (0.3) | 192.3 | 34.7 | (0.3) | 14.5 | (0.3) | (1.3) | (1.6) | 2.7 | (1.5) | (1.4) | (0.9) | (0.3) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (10.3) | 0 | 12.8 | 32.3 | 9.1 | 9.9 | 4.7 | (16.7) | 13.1 | 3.7 | (0.1) | 1.6 | 0.4 | 9 K | 60 K | 0 | 0.5 | 3.4 | 1.1 |
| Cash From Financing Activities | 61.7 | (7.5) | 212.1 | 262.9 | 217.5 | 450.8 | 247.4 | 272.7 | 290.9 | 139.2 | 29.4 | 81.5 | (0.9) | 43.7 | 2.8 | (1.0) | 91.9 | 66.2 | 41.3 |
| CHANGE IN CASH | |||||||||||||||||||
| Net Change In Cash | 97.0 | (96.3) | 83.3 | 19.8 | 64.0 | 31.1 | (138.0) | 117.5 | 45.4 | (19.6) | 9.7 | 8.3 | (3.9) | 10.2 | (8.7) | (16.1) | 32.1 | 5.7 | 6.2 |
| FREE CASH FLOW | |||||||||||||||||||
| Free Cash Flow | (76.5) | (170.3) | (206.4) | (236.5) | (270.4) | (306.3) | (220.0) | (156.5) | (105.0) | (51.9) | (46.5) | (38.1) | (50.8) | (14.4) | (45.2) | (39.5) | 14.5 | (35.9) | (21.2) |